reference/26051110

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/26051110

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	6, A6
issn	0002-9149
issueIdentifier	8
pageRange	884-6, A6
publicationName	The American Journal of Cardiology
startingPage	884
bibliographicCitation	Assali AR, Salloum J, Sdringola S, Moustapha A, Ghani M, Hale S, Schroth G, Fujise K, Anderson HV, Smalling RW, Rosales OR. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol. 2001 Oct 15;88(8):884–6, A6. doi: 10.1016/s0002-9149(01)01897-5. PMID: 11676953.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3c1dea9f5b96ef5299bda89ab363b584 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fbb521a05c2555db4a10f1e4d386f0d1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_33c80baf49bafa5184c595cb9f6aed60 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_42df8fc0b9e7ed1d0e26237a14548530 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a074e8bba192981d26f43c453b12b60f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_52e117595f2e1430947efddf9c229839 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_721925ced497b9ff95bc06619ac7c402 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a39dea38103b2b70ee9ee0fe8116cef8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ee5391c78e63004ce7eec13c74d7c0f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce22824bcd9e4b579beb4540c28f892d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b371d78e0ce147c5a401b9c3e4fadde2
date	2001-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/11676953 https://doi.org/10.1016/s0002-9149%2801%2901897-5
isPartOf	https://portal.issn.org/resource/ISSN/0002-9149 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/408
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban)
discusses	http://id.nlm.nih.gov/mesh/M0017012 http://id.nlm.nih.gov/mesh/M0011126 http://id.nlm.nih.gov/mesh/M0022203 http://id.nlm.nih.gov/mesh/M0227707 http://id.nlm.nih.gov/mesh/M0021526 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0155432 http://id.nlm.nih.gov/mesh/M0211213 http://id.nlm.nih.gov/mesh/M0028424
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D003327Q000628 http://id.nlm.nih.gov/mesh/D015607 http://id.nlm.nih.gov/mesh/D014443Q000627 http://id.nlm.nih.gov/mesh/D000911Q000627 http://id.nlm.nih.gov/mesh/D007140Q000627 http://id.nlm.nih.gov/mesh/D019039Q000037 http://id.nlm.nih.gov/mesh/D010975Q000627 http://id.nlm.nih.gov/mesh/D013988Q000627 http://id.nlm.nih.gov/mesh/D013988Q000031 http://id.nlm.nih.gov/mesh/D014443Q000031 http://id.nlm.nih.gov/mesh/D015906
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000077284 http://id.nlm.nih.gov/mesh/D000077466 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000077144 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D003327Q000188
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60606 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60947

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127968075 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127654660 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128918298 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459

Total number of triples: 64.